Vanguard Group Inc raised its holdings in shares of Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) by 2.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,798,708 shares of the company’s stock after buying an additional 47,361 shares during the quarter. Vanguard Group Inc’s holdings in Eyepoint Pharmaceuticals were worth $6,422,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Northern Trust Corp purchased a new position in Eyepoint Pharmaceuticals during the second quarter worth about $218,000. BlackRock Inc. purchased a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth about $304,000. California Public Employees Retirement System purchased a new position in shares of Eyepoint Pharmaceuticals in the 2nd quarter worth about $135,000. Private Advisor Group LLC purchased a new position in shares of Eyepoint Pharmaceuticals in the 3rd quarter worth about $134,000. Finally, Essex Investment Management Co. LLC boosted its holdings in shares of Eyepoint Pharmaceuticals by 65.0% in the 3rd quarter. Essex Investment Management Co. LLC now owns 134,509 shares of the company’s stock worth $480,000 after purchasing an additional 52,977 shares in the last quarter. Institutional investors and hedge funds own 52.13% of the company’s stock.

Shares of NASDAQ EYPT traded up $0.06 during midday trading on Monday, reaching $2.45. The company had a trading volume of 38,537 shares, compared to its average volume of 296,135. Eyepoint Pharmaceuticals Inc has a one year low of $0.93 and a one year high of $3.94. The company has a current ratio of 2.57, a quick ratio of 2.57 and a debt-to-equity ratio of 0.37. The firm has a market cap of $226.72 million, a PE ratio of -4.22 and a beta of 1.87.

A number of equities analysts have recently issued reports on EYPT shares. B. Riley upped their price objective on Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the stock a “buy” rating in a report on Tuesday, October 16th. ValuEngine raised Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 29th. Zacks Investment Research raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, November 13th. Finally, HC Wainwright set a $5.00 target price on Eyepoint Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, January 4th.

ILLEGAL ACTIVITY NOTICE: “Eyepoint Pharmaceuticals Inc (EYPT) Position Boosted by Vanguard Group Inc” was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://theolympiareport.com/2019/02/11/eyepoint-pharmaceuticals-inc-eypt-position-boosted-by-vanguard-group-inc.html.

Eyepoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Featured Story: Diversification For Individual Investors

Want to see what other hedge funds are holding EYPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT).

Institutional Ownership by Quarter for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.